Worldquant Millennium Quantitative Strategies LLC boosted its holdings in Celgene Co. (NASDAQ:CELG) by 21,330.1% in the fourth quarter, HoldingsChannel reports. The firm owned 724,122 shares of the biopharmaceutical company’s stock after buying an additional 720,743 shares during the quarter. Celgene comprises about 1.4% of Worldquant Millennium Quantitative Strategies LLC’s investment portfolio, making the stock its 8th largest holding. Worldquant Millennium Quantitative Strategies LLC’s holdings in Celgene were worth $46,409,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. LSV Asset Management boosted its holdings in shares of Celgene by 55.3% in the third quarter. LSV Asset Management now owns 87,037 shares of the biopharmaceutical company’s stock valued at $7,788,000 after acquiring an additional 31,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Celgene by 141.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 5,047 shares of the biopharmaceutical company’s stock valued at $452,000 after acquiring an additional 2,958 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of Celgene by 2.7% in the third quarter. Eagle Asset Management Inc. now owns 208,755 shares of the biopharmaceutical company’s stock valued at $18,681,000 after acquiring an additional 5,538 shares during the period. FormulaFolio Investments LLC boosted its holdings in shares of Celgene by 30.8% in the third quarter. FormulaFolio Investments LLC now owns 3,489 shares of the biopharmaceutical company’s stock valued at $312,000 after acquiring an additional 822 shares during the period. Finally, Granite Investment Partners LLC boosted its holdings in shares of Celgene by 26.8% in the third quarter. Granite Investment Partners LLC now owns 5,870 shares of the biopharmaceutical company’s stock valued at $525,000 after acquiring an additional 1,240 shares during the period. 73.84% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the company. Cowen assumed coverage on Celgene in a report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and issued a $100.00 price objective on shares of Celgene in a report on Thursday, January 31st. Jefferies Financial Group downgraded Celgene from a “buy” rating to a “hold” rating and set a $95.00 price objective for the company. in a report on Friday, February 1st. Zacks Investment Research raised Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price objective for the company in a report on Wednesday, January 23rd. Finally, William Blair reissued a “buy” rating on shares of Celgene in a report on Thursday, February 28th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Celgene currently has a consensus rating of “Hold” and a consensus target price of $100.94.
Shares of Celgene stock traded up $0.52 during trading hours on Thursday, hitting $88.89. 80,512 shares of the company were exchanged, compared to its average volume of 10,796,481. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $95.30. The company has a debt-to-equity ratio of 3.21, a current ratio of 2.23 and a quick ratio of 2.12. The stock has a market capitalization of $62.07 billion, a PE ratio of 11.62, a price-to-earnings-growth ratio of 0.40 and a beta of 1.69.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a return on equity of 114.66% and a net margin of 26.48%. The business had revenue of $4.04 billion during the quarter, compared to analysts’ expectations of $3.98 billion. During the same quarter in the prior year, the business earned $2.00 earnings per share. As a group, equities research analysts anticipate that Celgene Co. will post 10.01 EPS for the current year.
In other Celgene news, Director James J. Loughlin sold 23,466 shares of the stock in a transaction on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the transaction, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ernest Mario acquired 2,000 shares of the business’s stock in a transaction on Tuesday, February 12th. The stock was acquired at an average price of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. Corporate insiders own 0.39% of the company’s stock.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: Liquidity
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.